-
10:55
-11:03
Disease prognostication by clinico-radiomics signatures in ovarian clear cell carcinoma
-
11:03
-11:11
Impact of the first-line PARP inhibitor maintenance on platinum sensitivity and proteomic profiles in recurrent ovarian cancer
-
11:11
-11:19
A multiplexed genome engineering and single-cell framework reveals KrasG12D evolutionary traits in ovarian cancer
-
11:19
-11:27
Trastuzumab deruxtecan plus bevacizumab as first-line maintenance therapy for human epidermal growth factor receptor 2-expressing ovarian cancer: Safety run-in results from DESTINY-Ovarian01
-
11:27
-11:35
Response-independent overall survival benefit in the phase 3 ROSELLA Trial (APGOT-Ov10) of relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer
-
11:35
-11:43
Combined analysis of a novel articulated laparoscopic camera system in minimally invasive gynecologic surgery across two prospective studies
-
11:43
-11:55
Q&A

